ruthenium complex 4

Ruthenium complex 4 is a cyclometalated ruthenium(II) research compound containing 2-phenylimidazo[4,5-f][1,10]phenanthroline derivatives substituted with trifluoromethyl groups. It is a small molecule anticancer agent that functions by selectively targeting the mitochondria of cancer cells rather than genomic DNA, a mechanism that distinguishes it from traditional platinum-based therapies like cisplatin. This compound has demonstrated high lipophilicity and efficient cellular uptake, leading to potent cytotoxicity against various cancer cell lines, including cisplatin-resistant lung cancer (A549R) cells. It exhibits selective accumulation in malignant cells over normal cells, suggesting a potential for reduced off-target toxicity. Currently, ruthenium complex 4 is utilized as a tool in academic research and is not in clinical development or associated with a commercial sponsor.

Other names

cyclometalated ruthenium(II) complex 4